Clinical Trial

Next Generation Sequencing-based "Oncochip" for Therapeutic Decision in Metastatic Breast Cancer. Study SHARP

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 10, 2024 (before its estimated March 2025 completion). Its status may not reflect the trial's current state.
Summary
The present trial clinical proposes to randomize patients with cancer metastatic disease of the breast progressing on standard therapy to receive a treatment selected from 4 "targeted" drugs (a MEK kinase inhibitor, an mTOR kinase inhibitor, an of the enzyme involved in DNA repair PARP and an androgen receptor inhibitor) on the basis of possible presence of mutations in a panel of 61 genes analyzed on metastatic tissue from biopsy, or receive standard chemotherapy.
Trial Details
NCT Number NCT06727357
Lead Sponsor European Institute of Oncology
Conditions Breast Cancer, Metastatic Breast Cancer
Enrollment 38 participants
Start Date 2019-09-26
Primary Completion 2025-03 (estimated)
Study Completion 2025-03 (estimated)
Updated on ClinicalTrials.gov 2024-12-10